Every Form 4 that Palvella Therapeutics Inc (PVLA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PVLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PVLA filings page.
PALVELLA THERAPEUTICS, INC. (PVLA) director Christopher P. Kiritsy reported an option exercise and related share sale. On September 2, 2026, he exercised a fully vested stock option for 313 shares of common stock at an exercise price of $127.20 per share, a figure adjusted for the company’s 1-for-80 reverse stock split that became effective on April 23, 2024. He then sold 313 shares of common stock at $157.00 per share on the same date, and the exercised option position is reported as fully exhausted in this filing.
PALVELLA THERAPEUTICS, INC. (PVLA) reported that Chief Operating Officer Kathleen Goin exercised stock options covering 4,302 shares of common stock on August 19, 2026, at exercise prices of $7.14 and $9.08 per share, and sold 4,302 shares in multiple open-market transactions at prices between $150.62 and $156.77 per share. These trades were executed under a Rule 10b5-1 trading plan adopted on August 19, 2025, and the exercised options were fully vested.
Palvella Therapeutics, Inc. Chief Operating Officer Kathleen Goin reported a series of option exercises and share sales on July 15, 2026. She exercised stock options for 4,302 shares of common stock at exercise prices of $7.1400 and $9.0800 per share, then sold 4,302 common shares in four transactions at weighted average prices of $147.1365, $148.4018, $149.2667 and $150.2529 per share. After the final sale she held 0 common shares directly, while the options involved were fully vested, and all trades were effected under a Rule 10b5-1 trading plan adopted on August 19, 2025 and approved under the company’s insider trading policy.
Palvella Therapeutics director Matthew Pauls received a grant of stock options representing rights to buy 6,000 shares of common stock. The options have an exercise price of 154.84 per share and expire on June 29, 2036. They vest in 36 equal monthly installments, conditioned on his continued service, and his derivative holdings after this grant total 6,000 options.
Palvella Therapeutics Chief Operating Officer Kathleen Goin exercised stock options for 4,302 shares of common stock at strike prices of $7.14 and $9.08 per share, then sold 4,302 shares in open-market transactions on June 17, 2026 at weighted average prices around $110–$112 per share. The filing shows these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 19, 2025. Following the sales, she holds 0 shares of Palvella common stock directly, and no remaining option positions are listed in this filing.
Palvella Therapeutics CFO Matthew E. Korenberg exercised stock options to acquire 1,000 shares of common stock at $13.60 per share. Following the transaction, he directly owns 1,000 common shares and retains stock options covering 166,100 shares.
The exercised options have an exercise price of $13.60 and an expiration date of December 13, 2034. According to the vesting terms, 25% of the options vest on October 16, 2025, with the remaining 75% vesting in equal monthly tranches over the next 36 months.
PALVELLA THERAPEUTICS director Christopher P. Kiritsy received a grant of stock options covering 3,000 shares of common stock at an exercise price of $102.19 per share. These options expire on June 10, 2036 and vest on the earlier of the first anniversary of the grant or the next annual meeting of stockholders, subject to his continued service.
Palvella Therapeutics director George M. Jenkins received a grant of stock options for 3,000 shares of common stock. The options have an exercise price of $102.19 per share and expire on June 10, 2036. They vest on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, subject to his continued service. After this grant, he holds 3,000 options directly.
Palvella Therapeutics director Elaine J. Heron received a grant of stock options for 3,000 shares of common stock. These options carry an exercise price of $102.19 per share and expire on June 10, 2036.
The options vest upon the earlier of the first anniversary of the June 10, 2026 grant date or the company’s next annual meeting of stockholders, subject to Heron’s continued service through the applicable vesting date. Following this grant, Heron holds 3,000 stock options directly.
PALVELLA THERAPEUTICS, INC. director John Doux received a grant of stock options covering 3,000 shares of common stock. The options have an exercise price of 102.1900 per share and expire on 2036-06-10.
These options vest upon the earlier of the first anniversary of the 2026-06-10 grant date or the company’s next annual stockholder meeting, subject to his continued service. Following this compensation-related grant, Doux holds 3,000 stock options directly.
Palvella Therapeutics director Todd C. Davis received a new stock option grant. He was awarded options to buy 3,000 shares of common stock at an exercise price of $102.19 per share, expiring on June 10, 2036. The options vest on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, subject to his continued service.
Palvella Therapeutics director Tadd S. Wessel received a grant of stock options covering 3,000 shares of common stock. The options have an exercise price of $102.19 per share and expire on June 10, 2036. All 3,000 options are held directly after this transaction. The options vest on the earlier of the first anniversary of the June 10, 2026 grant date or the date of Palvella’s next annual meeting of stockholders, in each case requiring his continued service through the vesting date. This is a compensation-related grant, not an open-market share purchase or sale.
Palvella Therapeutics, Inc. Chief Operating Officer Kathleen Goin reported option exercises and share sales in the company’s stock. On May 20, 2026, she exercised stock options for 2,154 shares at $7.14 per share and 2,148 shares at $9.08 per share, acquiring 4,302 shares of common stock.
That same day, she sold a total of 4,302 common shares in open‑market transactions at weighted average prices of about $110.35, $111.30, and $111.90. The filing shows she held 0 common shares directly after these transactions. The sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on August 19, 2025, during an open trading window.
Palvella Therapeutics, Inc. Chief Operating Officer Kathleen Goin exercised stock options and sold shares in pre-planned trades. On April 15, 2026, she exercised options for 2,154 shares of common stock at $7.14 per share and 2,148 shares at $9.08 per share, acquiring a total of 4,302 shares.
That same day, she executed open-market sales totaling 4,302 shares of common stock in multiple transactions, at weighted average prices including $125.9647, $127.1254, $128.2349, $129.1692, and $130.33 per share, with underlying trade ranges from $125.53 to $129.70 as disclosed. The filing states these transactions were carried out under a Rule 10b5-1 trading plan adopted on August 19, 2025 during an open trading window. After these transactions, the report shows 0 shares of common stock held directly by Goin, and no remaining option positions are listed.
Palvella Therapeutics director John Doux received a grant of stock options covering 6,000 shares of Common Stock. The options were awarded at an exercise price of $129.00 per share and expire on April 13, 2036.
The grant vests in 36 equal monthly installments, conditioned on Doux’s continued service with the company on each vesting date. After this award, he holds 6,000 stock options directly under this grant.
PALVELLA THERAPEUTICS, INC. director George M. Jenkins made an open-market purchase of common stock. On March 30, 2026, he bought 445 shares of Palvella Therapeutics common stock at $112.30 per share. Following this trade, he directly holds 187,616 shares and has an additional 13,516 shares reported as indirectly held through the Eagles Mere Air Museum Foundation.
Palvella Therapeutics Chief Operating Officer Kathleen Goin exercised stock options to acquire 4,302 shares of common stock on March 18, 2026 at exercise prices of $7.14 and $9.08 per share. She then sold 4,302 shares in three open-market transactions at weighted average prices of $117.5632, $118.3681, and $119.0817, as disclosed in the footnotes. The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 19, 2025. Following the transactions, the report shows she holds no shares of Palvella Therapeutics common stock directly and no remaining derivative positions from these options.
Palvella Therapeutics director George M. Jenkins bought 4,000 shares of common stock at $125 per share in an underwritten offering that closed on February 27, 2026. This purchase, reported as an open-market or private transaction, increased his direct holdings to 187,171 shares. He also reports indirect ownership of 13,516 shares held by Eagles Mere Air Museum Foundation.
Palvella Therapeutics director Elaine J. Heron reported buying 2,400 shares of common stock in an underwritten offering at $125 per share on February 27, 2026. This open-market purchase increased her direct holdings to 47,812 shares of Palvella Therapeutics.
The Form 4 also reports 5,879 shares of common stock held indirectly by a trust associated with Heron, reflecting additional ownership beyond her directly held shares.
Palvella Therapeutics Chief Operating Officer Kathleen Goin reported option exercises and share sales in Common Stock of PALVELLA THERAPEUTICS, INC. On February 18, 2026, she exercised stock options for 4,302 shares at exercise prices of $7.14 and $9.08 per share, converting derivative awards into common shares.
That same day, she sold 4,302 common shares in open-market transactions at weighted average prices of $79.1569 and $79.9651 per share, with individual trades ranging from $78.75 to $80.00. After these sales, her directly held common stock position reported in this filing was 0 shares. All transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on August 19, 2025, and the stock option referenced is disclosed as fully vested.
Palvella Therapeutics, Inc. disclosed that its Chief Scientific Officer, Jeffrey S. Martini, received a stock option grant. On February 5, 2026, he was awarded options to purchase 64,318 shares of common stock at an exercise price of $76.43 per share, granted for no cash cost.
The option vests in equal monthly installments over 48 months, beginning February 5, 2026, and each vesting installment requires his continuous service through the applicable vesting date.
Palvella Therapeutics, Inc. granted its Chief Commercial Officer, Ashley Hartmann, a stock option for 38,517 shares of common stock on February 5, 2026. The option has an exercise price of $76.43 per share and expires on February 5, 2036.
The option vests in equal monthly installments over 48 months, starting February 5, 2026, and remains subject to Hartmann’s continuous service with the company through each vesting date. All 38,517 derivative securities are reported as directly owned following this grant.
Palvella Therapeutics President and CEO Wes Kaupinen received a grant of 124,603 stock options on February 5, 2026. The options have an exercise price of $76.43 per share and are held directly.
The award vests in equal monthly installments over 48 months starting February 5, 2026, contingent on his continued service. Following this grant, Kaupinen beneficially owns 124,603 derivative securities tied to Palvella Therapeutics common stock.
Palvella Therapeutics, Inc. reported that CFO and Treasurer Matthew E. Korenberg received a grant of stock options for 44,123 shares of common stock on February 5, 2026. The options carry an exercise price of $76.43 per share and expire on February 5, 2036.
The options vest in equal monthly installments over 48 months starting February 5, 2026, as long as he remains in continuous service through each vesting date. Following this award, he beneficially holds 44,123 derivative securities directly.
Palvella Therapeutics Chief Operating Officer Kathleen Goin reported receiving a stock option grant. On February 5, 2026, she was awarded options to purchase 48,956 shares of common stock at an exercise price of $76.43 per share, expiring February 5, 2036.
The options vest in equal monthly installments over 48 months starting February 5, 2026, and each vesting date requires her continued service. All 48,956 derivative securities are held directly following this grant.
Palvella Therapeutics Chief Operating Officer Kathleen Goin reported option exercises and related share sales in Palvella Therapeutics, Inc. common stock. On January 21, 2026, she exercised stock options for 2,154 shares at $7.14 and 2,148 shares at $9.08 per share. The resulting common shares were then sold in two transactions totaling 4,302 shares, with 553 shares sold at $95.49 and 3,749 shares sold at $97.94, leaving no directly held common stock reported after these sales. Following the option exercises, she continued to hold 19,397 and 19,332 stock options, each fully vested. The filing states that all transactions were carried out under a Rule 10b5‑1 trading plan adopted on August 19, 2025 during an open trading window and approved under the company’s insider trading policy.
Palvella Therapeutics (PVLA) reported insider transactions by its Chief Operating Officer on a Form 4. On 11/19/2025, the officer exercised stock options to acquire 2,154 shares of common stock at $7.14 per share and 2,148 shares at $9.08 per share. The same day, the officer sold 1,500 shares at a weighted average price of $85.7183 and 2,802 shares at a weighted average price of $86.5053, leaving 0 shares of common stock directly owned after these transactions.
The filing shows remaining fully vested stock options covering 2,154 shares expiring on 10/29/2029 and 2,148 shares expiring on 10/14/2030, with post‑transaction option holdings of 23,705 and 23,628 options in those grants. All transactions were carried out under a Rule 10b5‑1 trading plan adopted on August 19, 2025.